Skip to content
Back to CYRX

Cryoport, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
16
Purchases
0
Sales
16
Purchase value
$0.00
Sale value
$6.34M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Mark W SawickiChief Scientific Officer
4
Filed Nov 12, 2026Period of report Nov 10, 20260001104659-26-126370
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF110,000$19.9261$199.26K92,356Direct
Filing footnotes · 1
  1. F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.50 to $20.27, inclusive.
Open on SEC EDGAR
Daniel M HancockDirector
4Rule 10b5-1 plan disclosed
Filed Nov 12, 2026Period of report Nov 9, 20260001104659-26-126367
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 9, 2026
Common StockF1F274,379$20.207$1.50M69,052Direct
Filing footnotes · 5
  1. F1This transaction occurred automatically pursuant to a trading plan adopted by the reporting person on May 27, 2026.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.47, inclusive.
  3. F31/36 of the options vested on the 4th of each month for thirty-six months beginning on 1/4/2019.
  4. F41/12 of the options vested on the 17th of the month for twelve months beginning 6/17/2024.
  5. F51/12 of the options vested on the 6th of the month for twelve months beginning 7/6/2025.
Open on SEC EDGAR
Jerrell SheltonDirector · President, CEO
4Rule 10b5-1 plan disclosed
Filed Aug 11, 2026Period of report Aug 11, 20260001104659-26-094228
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF1F228,800$14.9092$429.38K1,201,814Direct
Filing footnotes · 2
  1. F1The transactions reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 11, 2026. The Rule 10b5-1 trading plan was terminated on August 11, 2026.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.66 to $15.16, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Edward J ZecchiniChief Digital and Tech Officer
4
Filed Jun 12, 2026Period of report Jun 10, 20260001104659-26-073630
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 11, 2026
Common StockF233,600$14.4714$486.24K109,719Direct
SaleJun 10, 2026
Common StockF11,400$15.2314$21.32K109,719Direct
Filing footnotes · 3
  1. F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.20 to $15.26, inclusive.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.33 to $14.615, inclusive.
  3. F31/12 of options vested on the 23rd of each month for twelve months beginning July 23, 2017.
Open on SEC EDGAR
Ramkumar MandalamDirector
4
Filed Jun 8, 2026Period of report Jun 5, 20260001104659-26-071506
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 8, 2026
Common StockF223,214$15.4412$358.45K67,894Direct
Filing footnotes · 3
  1. F1Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $15.48, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F31/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.
Open on SEC EDGAR
Robert StefanovichChief Financial Officer
4
Filed Jun 8, 2026Period of report Jun 4, 20260001104659-26-071509
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJun 4, 2026
Common StockF1169,427$16.2724$2.76M109,850Direct
Filing footnotes · 1
  1. F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.05 to $16.70, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open on SEC EDGAR
Robert StefanovichChief Financial Officer
4
Filed Mar 25, 2026Period of report Mar 23, 20260001104659-26-034754
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 23, 2026
Common StockF11,094$8.18$8.95K279,277Direct
Filing footnotes · 1
  1. F1Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
Open on SEC EDGAR
Jerrell SheltonDirector · President, CEO
4
Filed Mar 25, 2026Period of report Mar 23, 20260001104659-26-034753
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 23, 2026
Common StockF12,894$8.18$23.67K1,051,607Direct
Filing footnotes · 2
  1. F1Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
  2. F21/48 of options vested on the 6th of each month for forty-eight months beginning May 6, 2016.
Open on SEC EDGAR
Mark W SawickiChief Scientific Officer
4
Filed Mar 25, 2026Period of report Mar 23, 20260001104659-26-034752
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 23, 2026
Common StockF11,341$8.18$10.97K102,356Direct
Filing footnotes · 1
  1. F1Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
Open on SEC EDGAR
Edward J ZecchiniSee Remarks
4
Filed Mar 17, 2026Period of report Mar 14, 20260001104659-26-029720
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF22,014$8.00$16.11K109,719Direct
Filing footnotes · 3
  1. F1Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.
  2. F2Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
  3. F31/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.
Open on SEC EDGAR
Jerrell SheltonDirector · President, CEO
4
Filed Mar 17, 2026Period of report Mar 14, 20260001104659-26-029719
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF17,918$8.00$63.34K1,054,501Direct
Filing footnotes · 2
  1. F1Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
  2. F21/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.
Open on SEC EDGAR
Mark W SawickiChief Scientific Officer
4
Filed Mar 17, 2026Period of report Mar 14, 20260001104659-26-029718
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF23,235$8.00$25.88K103,697Direct
Filing footnotes · 3
  1. F1Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.
  2. F2Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
  3. F31/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.
Open on SEC EDGAR
Robert StefanovichChief Financial Officer
4
Filed Mar 16, 2026Period of report Mar 12, 20260001104659-26-028775
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleMar 16, 2026
Common StockF42,743$8.00$21.94K280,371Direct
SaleMar 12, 2026
Common StockF1F238,700$7.7619$300.39K255,701Direct
Filing footnotes · 6
  1. F1The proceeds of the sale of Common Stock were used to pay the exercise price and withholding taxes due upon exercise of the Stock Option reported in this Form 4.
  2. F2The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.725 to $7.83, inclusive.
  3. F3Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027.
  4. F4Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
  5. F51/48 of options vested on the 6th of each month for forty-eight months beginning May 6, 2016.
  6. F61/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026.
Open on SEC EDGAR
Ramkumar MandalamDirector
4
Filed Dec 12, 2025Period of report Dec 10, 20250001104659-25-120727
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 10, 2025
Common StockF111,570$9.9862$115.54K80,758Direct
Filing footnotes · 1
  1. F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.93 to $10.0696, inclusive.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.